Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pasireotide (SOM230) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers

NCT01128192
View directory record Official record
Conditions
Hyperglycemia
Interventions
pasireotide
Drug
Lead sponsor
Robert R. Henry, MD
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Sep 25, 2026, 4:59 PM EDT
Completed No phase listed Observational Results available

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

NCT02310269
View directory record Official record
Conditions
Cushings Disease
Interventions
Pasireotide
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 25, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

NCT01313559
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
Interventions
Pasireotide, Everolimus, Laboratory biomarker analysis
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

NCT00994110
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pasireotide (SOM230), placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

NCT01372644
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
Interventions
SOM 230 / Pasireotide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
View directory record Official record
Conditions
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
Interventions
Pasireotide, Cabergoline, Pasireotide LAR
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome

NCT01637272
View directory record Official record
Conditions
Dumping Syndrome
Interventions
SOM230
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
La Jolla, California • Stanford, California • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 25, 2026, 4:59 PM EDT
Withdrawn Phase 2 Interventional

SOM230 Ectopic ACTH-producing Tumors

NCT02780882
View directory record Official record
Conditions
Ectopic ACTH Syndrome
Interventions
Pasireotide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 25, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

NCT02619617
View directory record Official record
Conditions
Cluster Headache - Episodic and Chronic
Interventions
SOM230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Culver City, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 25, 2026, 4:59 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752
View directory record Official record
Conditions
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions
[177Lu]Lu-DOTA-TATE, Octreotide LAR
Radiation · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
20
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

NCT00813592
View directory record Official record
Conditions
Cancer
Interventions
SOM230B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

NCT00804336
View directory record Official record
Conditions
Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
Interventions
SOM230, RAD001
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

NCT00088582
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide (SOM230), Octreotide (Sandostatin)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 25, 2026, 4:59 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

NCT01372618
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
SOM 230 / Pasireotide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Sep 25, 2026, 4:59 PM EDT
Withdrawn Phase 2 Interventional

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

NCT01329289
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma
Interventions
SOM230, Bortezomib, Dexamethasone
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional

Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

NCT03103009
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia
Interventions
Pasireotide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

NCT01385956
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
SOM 230 LAR, Gemcitabine
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

NCT01582061
View directory record Official record
Conditions
Cushing's Disease
Interventions
Pasireotide sub-cutaneous
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
17
States / cities
Peoria, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01468532
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
docetaxel, pasireotide, prednisone
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

NCT00088608
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
SOM230 s.c.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

NCT01137682
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

NCT00171730
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

NCT01639352
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
SOM230
Biological
Lead sponsor
Lynn Feun
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 25, 2026, 4:59 PM EDT